Abstract
Beta-interferon was licensed for the treatment of multiple sclerosis in 1996. Since then it has been a controversial therapy. Availability of treatment has been varied from region to region. We audited the use of beta-interferon in the Grampian region, which has the largest cohort of patients treated in Scotland. One hundred and thirty seven patients were treated up to the beginning of 2002, 12.5% of the local MS population. The number of patients given treatment in Grampian continues to increase. Very few patients have discontinued treatment. The results of this audit show that our patients were treated in line with current clinical guidelines. This has implications for the implementation of guidelines in the rest of Scotland, where much smaller numbers of patients have been treated thus far. (127)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
